Robert Easton

This article is a stub. You can help by expanding it.

Biographical Information

"Dr. Robert Easton is a Managing Director and Co-head of Carlyle Europe Technology Partners, a team of dedicated investment professionals who focus on European growth capital and buyout opportunities in a variety of sectors including media, software, telecom, aerospace and defence, healthcare and technology. He is based in London.

"Since joining Carlyle in 2000, Dr. Easton has worked in both Europe Buyout and Europe Technology and has also been involved with a number of cross-fund transactions at Carlyle in the United States and Japan. He has sector expertise in chemicals, advanced materials, renewables, aerospace and defence.

"Prior to joining Carlyle, Dr. Easton was Vice President of Corporate Development at Invensys plc with responsibility for the execution of acquisitions and disposals. Dr. Easton was a key figure in the mid-nineties transformation of BTR from a diversified conglomerate to a focused engineering group and, following the merger of BTR and Siebe to form Invensys in 1999, in the further focusing of Invensys to become a leading Automation and Controls group. During this period of substantial change, he executed a total of 35 acquisitions and disposals with an aggregate value of €7 billion. Dr. Easton joined BTR in 1996 from Trafalgar House, another major U.K. engineering group where he was Director of Corporate Finance and Planning with responsibility for strategic planning and acquisitions and disposals.

"Prior to becoming a corporate development executive, Dr. Easton spent eight years in the investment banking business working initially for CSFB and then for a period of five years for Wasserstein Perella, a mergers and acquisitions specialist boutique.Dr. Easton has a first class honours degree in chemistry from Imperial College in London and a Doctorate in organic synthesis from Oxford University. Dr. Easton has been registered with the FSA since 2001, and is currently registered for the CF10, CF11, CF3 and CF30 controlled functions. Dr. Easton is currently a member of the Board of Directors of a number of Carlyle portfolio companies including Ensus. In addition to his Directorships of Carlyle portfolio companies, Dr. Easton is the Vice Chairman of the British Venture Capital Association (Chairman in 2012) a member of Walker Guidelines Monitoring Group for private equity disclosure and also sits on the Advisory Board of the Imperial College Business School."